溶血磷脂酸与卵巢肿瘤

Lysophosphatidic acid and ovarian cancer

溶血磷脂酸是一种具有细胞间信号传导作用的脂类小分子物质 ,具有广泛的生物学效应。研究发现卵巢癌患者的腹水中存在溶血磷脂酸 ,它可以促进癌细胞的生长 ;卵巢癌患者的血浆中具有明显高于正常对照组的溶血磷脂酸 ,用于卵巢癌的诊断具有较高的敏感性及特异性 ,优于Ca12 5。卵巢癌的细胞可分泌溶血磷脂酸 ,且细胞中存在溶血磷脂酸的自分泌环 ,它与肿瘤的发展、耐药及预后密切相关。这将为卵巢癌的治疗提供新的可能。

Lysophosphatidic acid(LPA), one of the simplest molecules of phospholipids, exhibits pleiomorphic biological functions. It has been found that lysophosphatidic acid is present at high level in the ascites fluid of ovarian cancer patients and can stimulate the development of cancer cells. The plasma LPA level of the ovarian cancer patients is also significantly higher than that of the controls. In the diagnosis of ovarian cancer, the plasma LPA is more sensitive and specific than that of Ca125. Ovarian cancer cells can secrete LPA and there is an autocrine loop in the cancer cells. LPA can increase the progression of ovarian cancers, resistance to cisplatin and metastasis, so it can affect the prognosis greatly. It indicated that LPA control should be possible to be a novel therapeutics for ovarian cancer.